
BioRegenx is a holding company focused on regenerative health solutions and proactive healthcare, offering products such as dietary supplements, medical devices, AI, DNA health testing, PEMF therapy, and hydrogen water. The company aims to capture market share by acquiring or licensing innovative intellectual property and products in the regenerative health and anti-aging sectors. With flagship products like Glyco Check and Endocalyx Pro, BioRegenx is positioned to leverage its extensive research and clinical studies to address various health conditions, thereby establishing a strong market presence in the $5 trillion health and wellness industry.

BioRegenx is a holding company focused on regenerative health solutions and proactive healthcare, offering products such as dietary supplements, medical devices, AI, DNA health testing, PEMF therapy, and hydrogen water. The company aims to capture market share by acquiring or licensing innovative intellectual property and products in the regenerative health and anti-aging sectors. With flagship products like Glyco Check and Endocalyx Pro, BioRegenx is positioned to leverage its extensive research and clinical studies to address various health conditions, thereby establishing a strong market presence in the $5 trillion health and wellness industry.
Headquarters: Chattanooga, Tennessee
Focus: Regenerative health technologies, nutraceuticals, non‑invasive diagnostics and AI monitoring
Flagship products: GlycoCheck, Endocalyx Pro, DocSun
Founded: 2021
Structure: Holding company with subsidiaries (e.g., Microvascular Health Solutions, MyBodyRx, NuLife Sciences)
Regenerative health, anti‑aging, microvascular diagnostics, proactive health monitoring
2021
Biotechnology
$183,000
“Entered a binding letter of intent to merge with a public company (July 2022) and later announced a definitive agreement to merge with Findit, Inc. (Dec 29, 2022).”